patient
enrol
may
april
univers
children
hospit
zurich
cap
clinic
defin
presenc
fever
tachypnea
accord
british
thorac
societi
bt
guidelin
elig
particip
inpati
outpati
age
year
cap
patient
year
age
exclud
reduc
probabl
viral
infect
highest
age
group
patient
hospitalacquir
pneumonia
cystic
fibrosi
chronic
lung
disord
exclud
asthma
known
primari
secondari
immunodefici
exclud
local
ethic
committe
approv
protocol
studi
number
written
inform
consent
obtain
parent
children
year
age
enrol
patient
investig
mp
pharyng
swab
sampl
specif
realtim
pcr
addit
consent
given
blood
sampl
collect
separ
peripher
blood
mononuclear
cell
pbmc
serum
serum
store
detail
elsewher
cap
patient
includ
studi
fresh
isol
hour
pbmc
avail
avoid
poor
elispot
assay
perform
test
presenc
mp
igm
asc
cap
patient
posit
mp
igm
asc
elispot
assay
result
consid
cap
caus
mp
mp
posit
mp
igm
asc
detect
patient
consid
cap
caus
anoth
etiolog
mp
neg
addit
investig
frequenc
mp
pcr
pharyng
swab
among
household
contact
avail
sampl
present
index
patient
studi
closur
pharyng
swab
sampl
kept
addit
test
streptococcu
pneumonia
sp
realtim
pcr
know
detect
sp
urt
like
colon
infect
fact
coinfect
sp
mp
uncommon
wherea
cocolon
may
common
anoth
viral
bacteri
respiratori
pathogen
test
use
eplex
respiratori
pathogen
panel
genmark
diagnost
carlsbad
california
previous
describ
addit
mp
serolog
perform
virionserion
germani
studi
test
result
avail
treat
clinician
demograph
epidemiolog
clinic
data
systemat
collect
use
standard
questionnair
full
recoveri
assess
month
enrol
chest
radiograph
order
clinic
reason
therefor
avail
patient
chest
radiograph
assess
radiologist
routin
clinic
care
radiolog
find
correspond
imag
retrospect
review
author
blind
clinic
inform
use
criteria
radiograph
pneumonia
blood
cell
count
creactiv
protein
crp
analysi
perform
part
routin
clinic
care
procalcitonin
pct
test
perform
retrospect
batch
analysi
result
avail
treat
physician
pct
level
measur
use
sensit
assay
detect
limit
ngml
pct
sensit
kryptor
thermoscientif
berlin
germani
nonparametr
mannwhitney
u
test
use
compar
continu
variabl
fisher
exact
test
compar
proport
mpposit
mpneg
group
calcul
area
receiv
oper
characterist
roc
curv
auc
clinic
featur
biomark
differenti
group
determin
mp
igm
asc
elispot
assay
refer
standard
consid
auc
adequ
discrimin
auc
differ
calcul
use
delong
test
miss
valu
remov
ignor
rocformula
best
biomark
threshold
defin
optim
cutoff
maxim
distanc
ident
diagon
line
roc
curv
accord
youden
j
statist
report
p
valu
statist
signific
defin
p
valu
data
analyz
use
r
softwar
environ
version
studi
period
cap
patient
enrol
mp
dna
detect
pcr
particip
enrol
popul
cap
patient
met
criteria
fresh
pbmc
avail
undergo
diagnost
test
mp
igm
asc
elispot
assay
includ
studi
mpposit
determin
detect
mp
igm
asc
detail
elsewher
mp
igm
ascposit
patient
also
mp
pcr
posit
igm
posit
howev
mp
pcr
also
posit
patient
mp
igm
asc
igm
neg
mp
igm
found
anoth
patient
mp
igm
asc
pcr
neg
chest
radiograph
perform
includ
cap
patient
whereof
met
criteria
radiograph
pneumonia
median
age
mpposit
patient
interquartil
rang
iqr
year
higher
compar
mpneg
patient
cap
iqr
year
p
tabl
mpposit
cap
like
mpneg
cap
present
summer
odd
ratio
confid
interv
ci
underli
diseas
less
common
among
mpposit
mpneg
patient
vs
p
mpposit
patient
significantli
like
mpneg
patient
receiv
prior
antibiot
treatment
ci
wherea
amoxicillin
without
clavulan
acid
frequent
agent
group
mpposit
n
vs
mpneg
n
posit
famili
histori
respiratori
tract
infect
rti
report
mpposit
compar
mpneg
patient
ci
p
household
contact
mpposit
index
patient
significantli
like
mp
detect
urt
mpneg
index
patient
ci
p
famili
member
mother
mpneg
index
patient
pcr
posit
rti
symptom
among
household
contact
mpposit
index
patient
mp
detect
urt
sibl
mother
father
report
rti
symptom
sibl
mother
asymptomat
carrier
durat
rti
symptom
fever
prior
cap
diagnosi
longer
mpposit
median
iqr
day
mpneg
patient
iqr
day
p
symptom
sign
statist
differ
group
mpposit
patient
differ
mpneg
patient
consolid
interstiti
infiltr
pleural
effus
extrapulmonari
manifest
observ
mpposit
children
cap
vs
p
includ
dermatolog
neurolog
disord
tabl
inclus
mpposit
patient
treat
antibiot
vitro
activ
mp
hospit
rate
length
hospit
stay
similar
group
detail
characterist
hospit
ambulatori
mpposit
mpneg
patient
shown
supplementari
tabl
among
hospit
patient
mpposit
patient
like
oxygen
demand
extrapulmonari
manifest
poor
outcom
mpneg
patient
sequela
observ
hospit
mpposit
patient
ie
bronchiol
obliteran
exert
dyspnea
postinflammatori
pigmentari
alter
mpneg
patient
fulli
recov
hematolog
assess
togeth
pct
crp
analysi
mpposit
mpneg
cap
patient
shown
tabl
mpposit
cap
patient
lower
white
blood
cell
wbc
count
absolut
neutrophil
count
anc
pct
crp
valu
mpneg
patient
figur
differ
clinic
featur
biomark
may
attribut
anoth
pathogen
caus
subset
infect
therefor
pharyng
swab
sampl
test
studi
pathogen
two
pathogen
found
urt
mpposit
mpneg
patient
tabl
sp
equal
detect
cohort
exclus
found
mpneg
patient
respiratori
syncyti
viru
rsv
n
p
influenza
viru
n
parainfluenza
viru
n
coronaviru
n
viru
statist
associ
mp
posit
rhinoviru
adenoviru
bocaviru
equal
detect
cohort
thu
also
compar
clinic
featur
biomark
mpposit
patient
follow
subgroup
mpneg
patient
n
first
posit
rsv
n
viru
detect
urt
high
predict
valu
cap
etiolog
second
posit
virus
rsv
n
awar
urt
detect
pathogen
rsv
may
relat
pneumonia
third
neg
virus
n
sp
detect
urt
addit
pleural
aspir
routin
clinic
care
howev
although
number
smaller
subanalysi
mpposit
cap
also
compar
subgroup
mpneg
cap
statist
associ
older
age
prolong
prodrom
respiratori
symptom
low
level
pct
supplementari
figur
supplementari
tabl
roc
analysi
perform
clinic
featur
biomark
associ
mpposit
cap
roc
curv
show
good
discrimin
abil
auc
differenti
group
age
auc
durat
prodrom
symptom
auc
pct
auc
crp
auc
figur
best
clinic
threshold
discrimin
mpposit
mpneg
patient
age
year
prodrom
fever
rti
symptom
durat
day
tabl
optim
biomark
threshold
pct
mgl
crp
wbc
count
anc
assess
mpposit
cap
posit
likelihood
ratio
highest
age
year
ci
durat
fever
day
ci
rti
symptom
day
ci
well
pct
ci
crp
mgl
ci
tabl
use
pct
cutoff
mpposit
patient
pct
concentr
cutoff
compar
mpneg
patient
p
mpposit
cap
patient
high
pct
level
ie
develop
bronchiol
obliteran
dermatolog
manifest
combin
clinic
featur
biomark
effect
diagnosi
mp
cap
compar
either
clinic
featur
biomark
alon
figur
improv
diagnost
perform
reach
combin
clinic
featur
ie
age
durat
prodrom
symptom
auc
ci
togeth
pct
auc
ci
p
tabl
evalu
clinic
featur
biomark
diagnos
mp
infect
within
welldefin
cohort
ambulatori
hospit
children
cap
mp
infect
diagnos
mp
igm
asc
elispot
assay
allow
differenti
mp
infect
carriag
diagnos
mp
caus
cap
earli
stage
import
avoid
ineffect
firstlin
empir
antibiot
evalu
target
treatment
mp
sever
case
sever
score
ratio
algorithm
predict
rule
report
diagnos
mp
infect
basi
clinic
featur
howev
previou
studi
found
reliabl
sign
symptom
differenti
mp
infect
cap
etiolog
potenti
mp
infect
misclassifi
infect
carriag
recent
demonstr
mp
igm
asc
elispot
assay
differenti
mp
infect
carriag
mp
dna
andor
igm
also
detect
healthi
control
children
n
test
neg
mp
igm
asc
elispot
assay
notabl
high
mp
detect
rate
cap
patient
studi
may
relat
inclus
age
year
mp
frequent
detect
coincid
mp
epidem
europ
studi
period
preval
estim
import
translat
diagnost
studi
find
clinic
practic
take
bay
theorem
account
posttest
probabl
diseas
presenc
higher
given
higher
pretest
probabl
preval
proper
implement
new
diagnost
test
clinic
practic
therefor
necessari
test
assess
context
diagnost
inform
avail
time
point
test
abl
corrobor
previou
studi
find
mpposit
cap
manifest
predominantli
schoolag
children
year
children
present
prodrom
fever
respiratori
symptom
day
significantli
longer
compar
cap
caus
etiolog
symptom
sign
well
radiograph
find
differenti
mpposit
mpneg
cap
extrapulmonari
manifest
predominantli
skin
disord
statist
associ
mpposit
cap
studi
presenc
significantli
increas
probabl
underli
mp
infect
may
also
true
presenc
rti
within
famili
mpposit
cap
patient
observ
frequent
rti
symptom
mp
detect
member
famili
support
previou
data
mp
spread
among
person
close
contact
famili
transmiss
mp
mp
infect
mild
selflimit
case
manifest
predominantli
previous
healthi
children
studi
onethird
mpposit
cap
patient
treat
antibiot
vitro
activ
mp
children
fulli
recov
bt
guidelin
advis
macrolid
antibiot
may
ad
age
case
sever
diseas
respons
firstlin
empir
treatment
prior
antibiot
treatment
associ
mp
cap
includ
treatment
antibiot
case
support
patient
respond
antibiot
mp
cap
consid
find
statist
differ
fever
durat
follow
cap
diagnosi
hospit
length
stay
recoveri
followup
mpposit
patient
receiv
antibiot
mp
data
shown
find
support
need
futur
intervent
studi
assess
effect
antibiot
mp
cap
studi
demonstr
mpposit
cap
biomark
level
pct
crp
wbc
count
anc
statist
lower
compar
mpneg
cap
despit
limit
number
even
true
pct
crp
mpposit
cap
comparison
viral
cap
rsv
subgroup
mpneg
cap
similar
trend
observ
previou
cap
studi
crp
wbc
count
anc
recent
pct
median
level
cap
consid
caus
mp
studi
conflict
result
suggest
higher
pct
level
associ
mp
may
hamper
diagnost
pct
cutoff
reach
best
discriminatori
power
differenti
mpposit
mpneg
children
cap
support
previou
studi
mpposit
patient
pct
level
cutoff
studi
sever
limit
first
though
sampl
perform
relev
popul
clinic
cap
studi
popul
small
repres
conveni
sampl
observ
studi
rule
unintend
select
occur
howev
even
though
sampl
size
small
predict
scope
studi
describ
risk
factor
mp
infect
second
mild
case
may
refer
tertiari
center
third
studi
enrol
children
year
age
reduc
probabl
viral
infect
howev
younger
children
mp
infect
may
like
rti
cap
conclus
improv
diagnost
help
identifi
clinic
featur
biomark
may
predict
mp
cap
children
age
year
underli
diseas
famili
rti
prior
antibiot
treatment
prodrom
respiratori
symptom
fever
day
well
extrapulmonari
skin
manifest
biomark
show
differ
mpposit
mpneg
patient
mp
posit
associ
low
level
crp
wbc
count
anc
pct
particularli
pct
cutoff
howev
studi
size
small
even
best
combin
clinic
featur
biomark
may
reliabl
enough
use
diagnost
data
support
combin
clinic
featur
biomark
may
help
physician
identifi
patient
high
risk
mp
cap
warrant
investig
larger
cohort
children
mp
infect
